ArticleTrials2022

Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.

Liping Dou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.